Innate Pharma (NASDAQ:IPHA) Downgraded by HC Wainwright to “Neutral”

HC Wainwright cut shares of Innate Pharma (NASDAQ:IPHA) from a buy rating to a neutral rating in a research note published on Thursday, MarketBeat.com reports.

A number of other analysts also recently weighed in on the stock. BTIG Research assumed coverage on shares of Innate Pharma in a research report on Monday, July 28th. They set a “buy” rating for the company. Leerink Partners reissued a “market perform” rating and issued a $2.00 price target (down previously from $10.00) on shares of Innate Pharma in a research report on Thursday. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Innate Pharma currently has a consensus rating of “Hold” and an average price target of $6.50.

Innate Pharma Trading Down 5.4%

Shares of NASDAQ IPHA opened at $1.94 on Thursday. The company has a 50 day simple moving average of $2.06 and a 200 day simple moving average of $2.02. Innate Pharma has a 1 year low of $1.29 and a 1 year high of $3.51. The company has a current ratio of 2.60, a quick ratio of 2.60 and a debt-to-equity ratio of 2.52.

About Innate Pharma

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.